In RAS-mutant cell lines, combinations of MEK/ERK, MEK/RAF and RAF/ERK inhibitors have shown enhanced antitumour activity [50,51,52] and some clinical trials combining RAF and MEK inhibitors in RAS-mutant cancers are ongoing. Here, MAP2K7 is linked to cancer.